Vaccine biotechnology company Novavax (NASDAQ: NVAX) announced better-than-expected revenue in Q2 CY2026, but sales fell by 76.3% year on year to $56.7 million. Its GAAP loss of $0.32 per share was 16.6% above analysts’ consensus estimates.

Is now the time to buy Novavax? Find out by accessing our full research report, it’s free.

"We're encouraged by the momentum we're seeing across our business as we continue to advance our strategy," said John C. Jacobs, President and Chief Executive Officer, Novavax.

Company Overview

Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ: NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.

Revenue Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Novavax’s demand was weak and its revenue declined by 18.9% per year. This was below our standards and is a sign of poor business quality.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Novavax’s recent performance shows its demand remained suppressed as its revenue has declined by 35.3% annually over the last two years.

This quarter, Novavax’s revenue fell by 76.3% year on year to $56.7 million but beat Wall Street’s estimates by 1.5%.

Looking ahead, sell-side analysts expect revenue to decline by 34.1% over the next 12 months, similar to its two-year rate. Although this projection is better than its two-year trend, it’s tough to feel optimistic about a company facing demand difficulties.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

Novavax’s high expenses have contributed to an average adjusted operating margin of negative 41.2% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle.

On the plus side, Novavax’s adjusted operating margin rose by 52.3 percentage points over the last five years. Zooming into its more recent performance, however, we can see the company’s margin has decreased by 26.9 percentage points on a two-year basis. If Novavax wants to pass our bar, it must prove it can expand its profitability consistently.

This quarter, Novavax generated a negative 96.8% adjusted operating margin. The company’s consistent lack of profits raises a flag.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

Although Novavax’s full-year earnings are still negative, it reduced its losses and improved its EPS by 35.6% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability.

In Q2, Novavax reported EPS of negative $0.32, down from $0.60 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Novavax to improve its earnings losses. Analysts forecast its full-year EPS will improve from negative $1.52 to negative $0.69.

Key Takeaways from Novavax’s Q2 Results

It was good to see Novavax beat analysts’ EPS expectations this quarter. We were also happy its revenue narrowly outperformed Wall Street’s estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock remained flat at $7.73 immediately following the results.

Indeed, Novavax had a rock-solid quarterly earnings result, but is this stock a good investment here? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).